Trevena Inc

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

Beleggen met ongekend lage tarieven?
Aandelen BE/NL €2+0,03% / VS €0,50+$0,004 p/st
Kernselectie: Geen kosten turbo's, ETF's en fondsen
DEGIRO: meer informatie / rekening openen


Gebruikersavatar
Sebbie
Premiummember
Premiummember
Berichten: 38
Lid geworden op: 07 feb 2012 16:49
waarderingen: 9
Contacteer:

Re: Trevena Inc

Bericht door Sebbie »

Guggenheim - price target 5$ :
Flanders tells investors. The analyst forecast sales of $1M in 2020, growing to $16M in 2021 and about $171M in 2025 for Olinvyk.
Tevens redelijk wat geld op de bank na de laatste kapitaalronde in augustus. Financieel kunnen ze blijkbaar nog door tot 2022.

Dit weekend nog eens verder over inlezen.
"Everyone has the brainpower to make money in stocks. Not everyone has the stomach.”







Volg Beursig.com op Twitter en Facebook


Gebruikersavatar
noobs_inc
Forum gebruiker
Forum gebruiker
Berichten: 139
Lid geworden op: 17 feb 2019 11:10
waarderingen: 128
Contacteer:

Re: Trevena Inc

Bericht door noobs_inc »

Zit hier vrij stevig in en volg dit op d.m.v. volgende bronnen:

Stocktwits, zoals de naam het zegt twitter voor stocks.
- Veel 'meningen' maar af en toe ook echt degelijke due dilligence van enkele posters.
https://stocktwits.com/symbol/TRVN

Yahoo finance, voor het volume / nieuws / en de graphs voor wat achterliggende TA.
https://finance.yahoo.com/quote/TRVN?p=TRVN

EUR/USD schommelingen ook op te volgen tenzij je hedged.

Iborrowdesk, voor het openstaand aantal aandelen die shorters kunnen lenen, hoe meer hoe beter hier dus.
https://iborrowdesk.com/report/TRVN

Marketchameleon, voor de pre- and aftermarket trades te kunnen bekijken.
https://marketchameleon.com/Overview/TR ... /Premarket

Shortsqueeze, om de open short interest te zien, op de nasdaq om de twee weken gereleased.
https://shortsqueeze.com//shortinterest ... php?s=TRVN

TheFly, voor mogelijke price target adjustments of rumours.
https://thefly.com/news.php?symbol=TRVN

Whalewisdom, voor de changes in institutional holdings.
https://whalewisdom.com/stock/trvn-2?se ... quarter=79

En uiteraard natuurlijk de press releases van trevena zelf:
https://www.trevena.com/investors/press-releases
piddybull liked last!
Searching sexy stock 2 stay in my portfolio. Req:YoY 120% return,Ready to be sold off to strangers,At least 30% shorted of the float.Symbol can't start with S,P or A. In return will pump and dump you.

Gebruikersavatar
noobs_inc
Forum gebruiker
Forum gebruiker
Berichten: 139
Lid geworden op: 17 feb 2019 11:10
waarderingen: 128
Contacteer:

Re: Trevena Inc

Bericht door noobs_inc »

Meer info over de pipeline:

TRV130 - oliceridine - merknaam Olinvyk, FDA approved, sales zouden moeten beginnen nu Q1 2021.
https://olinvyk.com/

TRV027 tegen blood clotting etc bij COVID-19, phase 1 readout in Q1 2021:
https://clinicaltrials.gov/ct2/show/stu ... w=2&rank=4
Gesponsord door Imperial college london, en die werken samen met de british heart foundation.

TRV250 tegen migraine, studie opgestart ooit in 2019 maar stopgezet vanwege pandemie, restart in H2 2021:
https://clinicaltrials.gov/ct2/show/NCT ... w=2&rank=1
Uitgevoerd door Trevena zelf.

TRV734 als middel tegen opioid addiction als afkickdrug, trial begint van zodra pandemie het toelaat, dus inschatting hier ook H2 2021:
https://clinicaltrials.gov/ct2/show/stu ... w=2&rank=3
Gesponsord via NIDA in de VS.

TRV045: S1P modulator tegen verschillende CNS ziekten, momenteel nog preklinisch, gesponsord via NIH in de VS.
piddybull liked last!
Searching sexy stock 2 stay in my portfolio. Req:YoY 120% return,Ready to be sold off to strangers,At least 30% shorted of the float.Symbol can't start with S,P or A. In return will pump and dump you.

Gebruikersavatar
noobs_inc
Forum gebruiker
Forum gebruiker
Berichten: 139
Lid geworden op: 17 feb 2019 11:10
waarderingen: 128
Contacteer:

Re: Trevena Inc

Bericht door noobs_inc »

Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts
Download as PDFJanuary 06, 2021 7:00am EST
--

Build-out of customer-facing team on track for this quarter

OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews

--

CHESTERBROOK, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today provided an update on the U.S. commercial launch for OLINVYK (oliceridine) injection and announced anticipated milestones for 2021.

“We enter 2021 focused on building upon the foundation we laid in 2020 to deliver a successful launch for OLINVYK. I’m pleased by the early interest we’ve received from hospital physicians and institutions across the country,” said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. “Additionally, we continue to make exciting progress across our pipeline, with several upcoming catalysts this year.”

OLINVYK Commercial Launch

OLINVYK commercially available. The Company has contracted with the three major wholesalers covering the majority of the acute care business. All three vial presentations of OLINVYK (1 mg/1 mL and 2 mg/2 mL single-dose vials; 30 mg/30 mL single-patient-use vials for patient-controlled analgesia) are now available for ordering.
Ramp-up of customer engagement activities underway. Since the approval of OLINVYK, the Company has received inbound interest from a diverse set of institutions and engaged with a number of key opinion leaders who participated in the Phase 3 OLINVYK “real-world” multi-site safety study. Physicians continue to reinforce the value proposition of OLINVYK as a compelling new analgesic option for acute pain patients in the hospital and other controlled clinical settings.

The comprehensive product dossier and detailed health economic model for OLINVYK are now complete and accessible to healthcare decision makers to facilitate formulary inclusion. The health economic model, which highlights OLINVYK versus IV morphine cost information, is expected to be published in 1H 2021.

In addition, the “Now Available” marketing campaign for OLINVYK has launched, which includes early digital engagement, launch emails to targeted healthcare professionals, and an updated website which provides product ordering and reimbursement information.
Build-out of customer-facing team on track for deployment this quarter. The Company has completed hiring of its medical science liaisons (MSLs) and sales manager team, and it remains on track to complete hiring, training and deployment of its field commercial team this quarter. The Company today announced that it will be targeting 100 formulary acceptances in 2021. In response to the ongoing COVID-19 pandemic, the Company is employing analytics on a local and regional basis to monitor the impact on hospitals and ambulatory surgical centers, and to inform the safe and effective deployment of its customer-facing teams.
All required CMS reimbursement submissions and registrations complete. The Company today announced that all submissions for permanent J- and C-Codes have been submitted to the Centers for Medicare and Medicaid Services (CMS) for OLINVYK. In the interim, as is customary for all new products, customers will use the miscellaneous J- and C-codes for reimbursement. This ensures that OLINVYK can be reimbursed in both the inpatient and outpatient setting until permanent codes are established. Market access resources are now available to customers which support reimbursement of OLINVYK at 95% of Average Wholesale Price (AWP) in advance of pass-through status being decided.
Pipeline Updates

COVID-19 trial for TRV027 on track to report topline data this quarter. TRV027 is being evaluated in a 60-person trial as a potential treatment for acute lung damage / abnormal blood clotting associated with COVID-19. Imperial College London is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.
IND filing for TRV045 on track for 1H 2021. In December 2020, the Company presented nonclinical data supporting the potential utility of TRV045 to treat a variety of CNS disorders, including epilepsy, chemotherapy-induced peripheral neuropathy, and diabetic peripheral neuropathy. The Company is currently collaborating with the National Institutes of Health (NIH) to evaluate TRV045 in their screening programs for epilepsy and non-addictive treatment of pain.
piddybull liked last!
Searching sexy stock 2 stay in my portfolio. Req:YoY 120% return,Ready to be sold off to strangers,At least 30% shorted of the float.Symbol can't start with S,P or A. In return will pump and dump you.

Gebruikersavatar
noobs_inc
Forum gebruiker
Forum gebruiker
Berichten: 139
Lid geworden op: 17 feb 2019 11:10
waarderingen: 128
Contacteer:

Re: Trevena Inc

Bericht door noobs_inc »

Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences
Download as PDFJanuary 07, 2021 7:00am EST
CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences, with additional details below.

LifeSci Partners 10th Annual Healthcare Corporate Access Event
Date: Friday, January 8th, 2021
Time: 2:00 p.m. ET
Format: Panel Discussion - Executing a Successful Product Launch During a Pandemic
Attendees: Carrie Bourdow, President & CEO
Webcast: https://wsw.com/webcast/lifesci/panel14/2387307

H.C. Wainwright BioConnect Conference
Date: Monday, January 11th, 2021
Time: 6:00 a.m. ET (webcast available)
Format: Fireside Chat
Attendees: Carrie Bourdow, President & CEO
Bob Yoder, Senior Vice President & Chief Commercial Officer
Webcast: https://journey.ct.events/view/940f6f19 ... a4e8e612e0
Links to the webcasts will be available on the Events page of the Investors section on the Company’s website at www.trevena.com/investors/events-presen ... r-calendar.
piddybull liked last!
Searching sexy stock 2 stay in my portfolio. Req:YoY 120% return,Ready to be sold off to strangers,At least 30% shorted of the float.Symbol can't start with S,P or A. In return will pump and dump you.


Deelnemen aan het forum + meer functies?

Deel kennis en vragen met duizenden beleggers,
minder advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!



Plaats reactie